WATERBURY, Conn., Dec. 18 /PRNewswire-FirstCall/ -- DiaSys Corporation a global healthcare products company, announced today that it has signed a five year contract renewal distribution agreement with Laboratory Diagnostics in Australia for territories covering Australia, New Zealand, Papua New Guinea and the Solomon Islands. The agreement guarantees minimum purchase orders of $615,000 for the Company's parasitology disposable products over the five-year period. Laboratory Diagnostics also represents, Binax and Diesse Diagnostics.
"We are pleased to continue our relationship with Laboratory Diagnostics, as they successfully introduced Parasep into the Australian market three years ago. Our new solvent free fecal concentration device, Parasep SF will be introduced into these territories in the first half of 2007," said Gregory Witchel, Chief Executive Officer.
DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and through distributors. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation. DiaSys's web address is http://www.DiaSys.com
Laboratory Diagnostics is a Company dedicated to sourcing and providing innovative niche quality products and solutions from a number of internationally recognized manufacturers. These products are provided to the diagnostic pathology laboratories, Veterinary pathology laboratories and research organizations in Australia, New Zealand and the South Pacific. Laboratory Diagnostic's web address is http://www.labdiagnostics.com.au
This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company.